Molecular epidemiology studies of cancer in families. by Li, F. P.
Be8 Macmillan Press Ltd., 1993
REVIEW
Molecular epidemiology studies of cancer in families
F.P. Li
Dana Farber Cancer Institute and Harvard School ofPublic Health, 44 Binney Street, Boston, Massachusetts 02115, USA.
Almost all cancers show the tendency to aggregate in
families. Close relatives of a cancer patient can be considered
to have increased risk of at least that form of cancer, and
perhaps other cancers. The fraction of a cancer that is
hereditary (number of hereditary cases/total number of the
cancer) varies substantially. On average, the excess site-
specific cancer risk associated with a positive family history is
approximately of 2 to 3-fold above the baseline rate (Wil-
liams & Strong, 1985; Mulvihill et al., 1977). Inherited
susceptibility accounts for a high proportion of certain rare
forms of cancer, such as the MEN (multiple endocrine neo-
plasia) syndromes (Knudson, 1985). However, the hereditary
fraction is much smaller for cancers due primarily to
environmental carcinogens, such as lung cancers.
Among cohorts of individuals exposed to such potent car-
cinogens as asbestos or ionising radiation, relatively few
develop cancer as a consequence (Li, 1988). In contrast, the
risk of cancer development approaches 100% for carriers of
certain cancer genes. These cancer genes are among the
several hundred single-gene traits that have been associated
with cancer development (Mulvihill et al., 1977). A point
mutation in retinoblastoma gene, for example, confers a 90%
likelihood of the cancer (Friend et al., 1988). These carriers
often develop multiple lesions in both eyes at unusually early
ages, and subsequently second primary cancers of other
organs. Despite its rarity, retinoblastoma has been studied as
the model of hereditary cancers in humans (Knudson, 1978).
Studies of the retinoblastoma gene, Rb, have yielded the
first human tumour suppressor gene (Cowell & Hoggs, 1992).
Isolation of the gene was made through a series of clinical,
cytogenetic and molecular studies. Clinical observations
showed that retinoblastoma is inherited in an autosomal
dominant pattern with high penetrance. All retinoblastoma
patients with a family history of the tumour or with bilateral
lesions have the hereditary disorder. Approximately 10% of
unilateral tumour non-familial cases also have the hereditary
neoplasm due to a new germinal mutation. Among retino-
blastoma cases, a few were observed to have severe mental
retardation and birth defects such as microcephaly, colobo-
mas of the eye, and hypertelorism. Chromosome banding
studies of these patients showed a consistent inborn deletion
at chromosome 13ql4. Additional studies showed that isolated
retinoblastoma families have constitutional rearrangements
that resulted in loss of alleles on chromosome 13q14
(Cavenee, 1983). Complementary biochemical studies
revealed loss of esterase D alleles on chromosome 13q14 in
retinoblastoma specimens (Cowell & Hoggs, 1992). Based on
the Rb gene mapping data, Friend et al. (1986) isolated the
retinoblastoma gene from chromosome 13ql4. Loss of the
Rb gene is associated with tumour development; the gene
functions as a tumour suppressor. Somatic mutations in the
retinoblastoma gene were found within a wide spectrum of
cancers, including sarcomas and carcinomas of the breast,
bladder, lung and other sites (Harbour et al., 1988; Lee et al.,
1987). The gene product has also been shown to bind the
transforming protein of several oncogenic viruses, including
T antigen of SV-40 virus and adenovirus EIA protein
(DeCaprio et al., 1988).
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Knudson's studies of retinoblastoma patients yielded his
2-mutation hypothesis. The model provides the conceptual
framework for studying rare families aggregates of virtually
any cancer to gain new understanding of human carcino-
genesis (Knudson, 1983, 1985). He proposed that at least two
mutations are required to transform a normal cell into a
cancer cell. At the molecular level, familial and sporadic
(non-familial) forms of a cancer involve the same gene(s). In
sporadic cancers, no mutation is inherited and two somatic
mutations must occur within one cell. Hereditary cancer is
due to a germinal mutation that has been inherited from a
parent and propagated in all somatic cells of susceptible
family members; a second mutation transforms the cell. The
hypothesis implies that any somatic cell of cancer gene-
carriers can be examined for the first mutation. A com-
parison of the tumour and somatic cells of these patients can
reveal the second and subsequent mutations. Experimental
confirmation of the Knudson model for retinoblastoma led
investigators to study other cancer families for additional
tumour suppressor genes.
The sequence of clinical, epidemiological and laboratory
studies of hereditary retinoblastoma have been employed in
studies of other familial cancers, particularly childhood
cancers. Of these, Wilms' tumour is associated with specific
malformation syndromes, such as aniridia, Beckwith-
Wiedemann syndrome and Denys-Drash syndrome (Grundy
et al., 1988; Coppes et al., 1992). The aniridia-Wilms' tumour
syndrome was shown to be due to a constitutional deletion of
chromosome 11p13; a Beckwith-Wiedemann syndrome gene
has been mapped to a chromosome lp15. In Wilms' tumour
cells, deletions of chromosome lip have been detected in
many specimens, suggesting that Wilms' tumour suppressor
gene(s) are present on chromosome lp. In 1990, the Wilms'
tumour suppressor gene on lIpl3, WT-1, was isolated
(Pritchard-Jones et al., 1990). WT-1 mutations appear to
cause the genitourinary anomalies associated with Wilms'
tumour, including Denys-Drash syndrome (Coppes et al.,
1992). Work on the lip15 locus is in progress. However, the
gene locus for a familial form of Wilms' tumour does not
appear to map to chromosome Ilp. Independent studies of
two large Wilms' tumour families excluded linkage to multi-
ple lip markers (Huff et al., 1992). The findings raise the
prospect of several heritable Wilms' tumour gene(s) on
chromosome 11 and another elsewhere in the genome. It is
unclear whether these genes are involved in alternative path-
ways in the pathogenesis of Wilms' tumour, or represent
different steps in its multistage development. The genetic
alterations in Wilms' tumour appear more complex than
those for retinoblastoma, and may be more relevant to the
common cancers in adulthood.
More is known about the genetics of carcinoma of the
colon than other cancers in adults, largely due to the work of
Vogelstein and his colleagues (Vogelstein et al., 1988, 1989).
Colorectal carcinoma develops in nearly all patients with
dominantly inherited adenomatous polyposis coli (APC) and
Gardner's syndrome (polyposis of the colon and stomach
associated with osseous tumours of the jaw, skull and other
sites, fibromas of the mesentery and skin, and carcinoma of
the ampulla of Vater) (Bodmer et al., 1987). The frequency
of polyposis in the general population is in the order 1 per
10,000 persons. Colon cancers in polyposis gene carriers tend
Br. J. Cancer (1993), 68, 217-219218 F.P. LI
to arise at early ages, occasionally in teenagers and at multi-
ple foci in the bowel. Initial mapping of the APC gene was
accomplished through study of a single patient with poly-
posis, multiple malformations, mental retardation, and a con-
stitutional deletion of chromosome 5ql3-22 (Bodmer et al.,
1987). The APC gene was isolated in 1991 and appears to
account for nearly all polyposis cases (Kinzler et al., 1991).
However, inherited APC mutations have not been detected in
familial colon cancer without polyposis, suggesting additional
hereditary 'colon cancer genes' (Peltomaki et al., 1992).
Analyses of colon tumour tissue from diverse patients have
revealed multiple genetic alterations (Fearon et al., 1990). On
average, colon carcinomas appear to have deletion of nearly
20% of all alleles in a non-random distribution (Vogelstein et
al., 1989). These include chromosome 5q deletions that span
the APC gene and a second colon cancer-associated gene,
MCC (missing in colon cancer). Deletions of chromosome 17
involve the p53 tumour suppressor gene, and deletions of
chromosome 18 involve the DCC (deleted in colon cancer)
gene (Kinzler et al., 1991). In addition, activating mutations
of ras and myc oncogenes have been found in colon cancers.
Epidemiological studies show that a family history of
breast cancer is a consistent risk factor for the neoplasm
(Sattin et al., 1985). In affected families, the risk may be
transmitted through either parent, and males have been
affected in some kindreds. Some breast cancer in families
manifest an autosomal dominant pattern with high pene-
trance. Patients at highest risk have a family history of
premenopausal, bilateral breast cancer affecting both mother
and maternal grandmother, or both mother and sister.
Cytogenetic analyses show that breast cancer cells are aneup-
loid and karyotypes are difficult to interpret. Several
chromosome regions show non-random losses, and several
oncogenes have been shown to be activated by point muta-
tion (ras) or gene amplification (Her-2/neu). Recently the
major gene locus for familial breast cancer and familial
breast-ovarian cancer of early onset was mapped to
chromosome 17q (Narod et al., 1991). Intensive efforts are
under way to isolate this important breast cancer gene.
Another common form of cancer in industrialised nations,
carcinoma of the prostate, displays a similar familial
tendency. A recent hospital-based study of male relatives of
691 consecutive prostate cancer patients showed an odds
ratio of 2 for men with an affected first-degree relative or
second-degree relative, and 8.8 for those with both an
affected first- and second-degree relative (Steinberg et al.,
1990; Carter et al., 1992). The risk increases with the total
number of affected family members. Familial prostate cancer
also tends to occur at early ages, and accounts for a substan-
tial fraction of the disease in younger men. The study sup-
ports earlier reports of a familial tendency of prostate cancer,
but the location of the gene(s) remains unknown.
Families have been reported with cancers at multiple
anatomic sites. Fraumeni and I have described family cancer
syndrome of breast cancer in young women and childhood
sarcomas and other neoplasms (Li et al., 1988). The synd-
rome was initially identified in a series of families with an
autosomal dominant pattern of these tumours. Prospective
follow-up ofcandidate families was conducted, which showed
an excess of the component neoplasms during follow-up
observation that appears to be free of ascertainment bias
(Garber et al., 1991). Additional studies of the syndrome
revealed an excess of breast cancers among mothers of
population-based series of children with sarcoma. Also,
segregation analysis of a series of children with soft-tissue
sarcoma showed evidence for transmission of a dominant
cancer susceptibility gene. To date at least seven component
cancers of the syndrome have been reported: breast cancer,
soft tissue sarcoma, osteosarcoma, acute leukaemia, brain
tumours, adrenocortical carcinoma, and gonadal germ cell
tumours. The possibility exists of other component neop-
lasms which tend to occur at early ages. In 1990, a search for
germ line mutations in known tumour suppressor genes
among these families revealed point mutations in the p53
genes in five affected kindreds (Malkin et al., 1990). As in the
retinoblastoma paradigm, tumour specimens from these
patients showed loss of the second wild-type (normal) allele.
The mutations tend to be localised in the evolutionary con-
served portions of the gene. There are families with Li-
Fraumeni syndrome that do not appear to have any germinal
p53 mutations. It is uncertain whether the finding is due to
undetected p53 mutations or to genetic heterogeneity. In
addition, rare patients have been reported with germ line p53
mutations but not a family history of the syndrome (Malkin
et al., 1992). These patients raise the possibility that pene-
trance of the germ line mutation might be lower than that
reported previously (Strong et al., 1992).
Caution is needed to avoid pitfalls in studies of the
molecular epidemiology of familial cancers, which can also
be due to shared environmental influences. or chance associa-
tion (Li, 1988). The distinction between inherited suscep-
tibility and chance association can be particularly difficult in
families with common forms of cancer, such as carcinomas of
the breast and colon. One person in three in the United
States and other industrialised nations develops an internal
malignant neoplasm within the course of a lifetime. The
lifetime cancer risk is one in two when carcinomas of the skin
are included in the analysis. The 240 million persons in the
US will form many striking family aggregates of cancer by
chance. A family history of cancer is, therefore, the rule and
not the exception. Several clinical features have been de-
scribed in hereditary cancers: specificity of the cancers by
organ site or tissue of origin, earlier age of occurrence than is
usual for that neoplasm, multifocal cancers of polyclonal
origin within the susceptible organ, and development of mul-
tiple primary cancers in individual patients. Unfortunately,
these findings are not highly specific indicators of genetic
predisposition (Schneider et al., 1986).
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